The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and Samsung Bioepis’ first steps into the Australian market.
‘Now is best time to develop Korean blockbuster drug’ (Korea Biomedical Review)
The local pharmaceutical industry needs various funding tools like M&A and a megafund to develop a Korean blockbuster drug that can generate over $1 billion annually, an expert said.
Prestige Biopharma to open vaccine production centre in South Korea (BioSpectrum Asia)
Prestige Biopharma Limited (PBP), based in Singapore, has announced that the company will be introducing a vaccine development and production centre into its core business.
Korean drugmakers to mass-produce Russia’s Sputnik V Covid-19 vaccine (Korea Biomedical Review)
Two consortia of Korean pharmaceutical companies said Friday they have agreed to make more than a billion doses of the Sputnik V Covid-19 vaccine developed by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology.
Samsung Bioepis continues global market expansion (BioSpectrum Asia)
Biopharmaceutical firm Samsung Bioepis, based in South Korea, has announced its expansion of its global footprint to Australia with the launch of HADLIMA™ (adalimumab), a biosimilar referencing HUMIRA (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa and plaque psoriasis.
Korea to launch blockchain-based vaccine certificate this month (Ledger Insights)
Prime minister Chung Sye-kyun is reported as saying “we have already completed the development of a system that can easily prove vaccination on a smartphone,” according to Yonhapnews.
Add Your Comment
You must be logged in to post a comment.